Drug intelligence / Profile preview

erythropoietin + angiotensin-converting-enzyme inhibitor + angiotensin II receptor blocker

Development stage
Unknown
Lead developer
Amgen
Administration
Intravenous, Subcutaneous, Oral
01

Overview

This represents a combination of three distinct types of medical treatments: erythropoietin (a hormone used to stimulate red blood cell production), an ACE inhibitor (a class of drugs that block the conversion of angiotensin I to angiotensin II), and an ARB (a class of drugs that block angiotensin II receptors). While erythropoietin may be used alongside either an ACE inhibitor or an ARB in certain clinical situations, the combination of ACE inhibitors and ARBs together is generally contraindicated due to significant risks of adverse effects, including acute kidney injury, hyperkalemia, and potentially increased cardiovascular mortality. Therefore, this specific triple combination is not recommended in standard clinical practice.

Other names
EPO + ACEI + ARB
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)ACE (Angiotensin Converting Enzyme)Erythropoietin ReceptorPPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on erythropoietin + angiotensin-converting-enzyme inhibitor + angiotensin II receptor blocker.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on erythropoietin + angiotensin-converting-enzyme inhibitor + angiotensin II receptor blocker.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call